arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Alkermes plc.

ALKS
$49.18 ▲ +0.77 (+1.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

Alkermes plc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $8.2B
Dividend Yield
Revenue Growth 27.0%
Op. Margin 3.7%
ROIC -0.1%
FCF / Share $0.82
Trailing P/E
Price / Book 4.6x
FCF Yield 1.7%
Debt / Equity 0.84
info Valuation on last close. End-of-day price, Aug 7, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$496.01M
↑ +27.0%
Net Income Profit after all expenses
$-66.48M
— 0.0%
Operating Margin Operating profit as % of sales
3.7%
↑ +130.1% 71th
FCF / Share Free cash flow per share
$0.82
↑ +180.3%
Long-Term Debt Long-term obligations
$1.52B
— 0.0%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
80
Returns
77
Cash Quality
86

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters